Manufacturer Self-Pay Now Undercuts Part of the Compounded Market
Approved-product cash pricing has fallen into the range compounded programmes occupy, reversing the assumption the category was built on.
For most of the compounding era one assumption held: an FDA-approved product would always cost more than a pharmacy preparation. Manufacturer self-pay pricing has broken that at the lower doses.
The consequence for a cash payer is direct. An approved route carries pre-market review, manufacturing under a federal quality system and supply-chain traceability that no compounded preparation has. Where the prices converge, the compounded route stops being the cheaper option and becomes only the less regulated one.
Any comparison listing only compounded programmes is now answering an out-of-date question. Ours name the manufacturer self-pay prices alongside them, at the semaglutide comparison and the tirzepatide comparison.
The numbers behind this page
Three questions to ask before acting on this report
Every price quoted in this report comes from the programme's own pricing page and carries the date it was captured.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
The figures in this report sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the cheapest verified semaglutide rate of $133 a month, medication alone runs $1,596 a year, $4,788 over three and $7,980 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
What a longer horizon costs
The figures in this report sit inside a market with a measurable shape, and that shape is what makes any single price readable.
At the cheapest verified semaglutide rate of $133 a month, medication alone runs $1,596 a year, $4,788 over three and $7,980 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What is the cheapest verified GLP-1 programme?
Oak Longevity at $133 a month for semaglutide and Found at $169 for tirzepatide, both at standard therapeutic dosing.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.